Exagen Inc. (XGN) financial statements and ratios from SEC XBRL: revenue $0.1B (TTM), net margin -30.0%, revenue growth 19.7% YoY. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (latest FY) | $66.58M |
| Revenue (TTM) | $0.1B |
| Net Margin | -30.0% |
| Operating Margin (TTM) | -18.2% |
| Net Debt / EBITDA | 0.2 |
| Revenue Growth (YoY) | 19.7% |
| EPS Growth (YoY) | 12.0% |
| FCF Growth (YoY) | 3.4% |
| Price / Book | 15.02 |
| Price / Sales | 2.56 |
| FCF Yield | -21.6% |
| Altman Z-Score | -3.82 (distress) |
| Piotroski F-Score | 3/9 |
| Piotroski checks passed | 3 of 9 |
| Industry P/E (Healthcare Services) | 25.4 |
| Sector P/E (Healthcare) | 21.9 |
XGN overview · XGN earnings · XGN KPIs · XGN documents · XGN ownership · XGN peers
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.